Navigation Links
Adeona's Multiple Sclerosis Trial Receives $409,426 Grant
Date:3/28/2011

been recently diagnosed with relapsing-remitting MS. With 127 out of 150 patients enrolled in the clinical trial by March 1, 2011, the Company anticipates full enrollment by the second half of 2011. Additional information regarding this multiple sclerosis clinical trial is available at http://www.clinicaltrials.gov/ct2/show/NCT00451204.

About Adeona Pharmaceuticals, Inc.

Adeona is a pharmaceutical company developing innovative medicines for the treatment of serious central nervous system diseases. The Company's strategy is to license product candidates that have demonstrated a certain level of clinical efficacy and develop them to a stage that results in a significant commercial collaboration. Currently, Adeona is developing the following product candidates: a prescription medical food for Alzheimer's disease, and drugs for multiple sclerosis, fibromyalgia, age-related macular degeneration and rheumatoid arthritis. For more information, please visit Adeona's website at www.adeonapharma.com.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "could," "potential," "positions," "continue," "expects," "anticipates," "intends," "plans," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding our ability to produce a new, effective oral therapy for multiple sclerosis and the anticipated enrollment. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-l
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
2. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
3. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
4. Kosan Opens Registration Program for Lead Hsp90 Inhibitor, Tanespimycin, in Multiple Myeloma
5. Multiple NIH Phase 2 HIV Vaccine Trials Using Vicals Technology Produce Encouraging Results
6. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
7. Kosan Receives Completed Special Protocol Assessment for TIME-1 Pivotal Phase 3 Trial of Tanespimycin in Multiple Myeloma
8. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
9. Pharmacopeia Announces Positive Results from Phase 1 Multiple Ascending Dose Study of PS433540 (DARA)
10. Phase III Clinical Trial in Newly Diagnosed Multiple Myeloma Stopped Early Due to Highly Significant Efficacy Advantage of VELCADE(R) (Bortezomib) for Injection Based Therapy Across All Endpoints
11. Velcura Therapeutics, Inc. Reports Positive Pre-IND Meeting With FDA and Plans Early Clinical Trials for New Drug to Treat Multiple Myeloma Bone Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 ... Market Research Report on Global and China Lysine ... is a professional and the deep research report ... introduces Lysine basic information including definition, classification specifications, ... as US, Europe , ...
(Date:4/17/2015)... 17, 2015 Inivata, a ... that their presence at the 2015 American Association for Cancer ... co-founder Nitzan Rosenfeld and a poster presentation. ... th - 22 nd . The presentation, ... , forms part of a session on ...
(Date:4/17/2015)... CVS Health Corporation (NYSE: CVS ) ... 1, 2015, at 8:30 a.m. (EDT) with analysts and ... An audio webcast of the conference call will ... the CVS Health website for all interested parties. To ... will be archived and available on the web site ...
Breaking Medicine Technology:Lysine Market International (US, Europe, Japan) Research Analysis 2Lysine Market International (US, Europe, Japan) Research Analysis 3Lysine Market International (US, Europe, Japan) Research Analysis 4Lysine Market International (US, Europe, Japan) Research Analysis 5Inivata Co-founder Nitzan Rosenfeld to Present at AACR Annual Meeting 2
... , DES MOINES, Iowa, Oct. 12 Briggs, a ... reduce operating costs in the home care market, today ... mandated by the Centers for Medicare & Medicaid Services ... proprietary documentation for all OASIS assessment forms as well ...
... 12 The University of Kansas Hospital has deployed ... provide physicians, nurses, and pharmacy staff in its neonatal ... and reference information. , The University of ... specializes in heart disease, cancer treatment and prevention, neurology, ...
Cached Medicine Technology:Regulatory Leader in OASIS Documentation Introduces OASIS-C Products 2University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 2University of Kansas Hospital Deploys NeoFax from Thomson Reuters for Electronic Neonatal Drug Dosing to Support Medication Safety 3
(Date:4/17/2015)... (PRWEB) April 17, 2015 John Evans, ... Party on the Patio from 2 p.m. to 3 ... located at 1320 Executive Ct. in Pekin, Illinois, serves ... who need some help to maintain their independence. , ... and tropical treats will be served during the luau. ...
(Date:4/17/2015)... Alcohol and Violence , The National Council on ... driving has been the focus of much public and ... between alcohol and crime received less public attention. , ... assault, and their relationship to alcohol have been clearly ... in America were drinking alcohol at the time of ...
(Date:4/17/2015)... In Defense of Christians (IDC) Executive ... Wednesday April 15th, the European Parliament joined its voice ... the Armenian Genocide, “paying tribute, on the eve of ... innocent Armenian victims who perished in the Ottoman Empire.” ... for this timely and needed recognition of a tragic ...
(Date:4/17/2015)... Hills, California (PRWEB) April 17, 2015 ... stands above in his new offering of platelet-rich plasma ... Orthopedic Sports Medicine (MOSM) is known for its ... Dr. Meier brings extensive surgical experience lacking in many ... and stem cell treatments are utilized for pain management ...
(Date:4/17/2015)... Fla. (PRWEB) April 17, 2015 Baptist ... Center have signed a partnership agreement designed to transform ... , The institutions have agreed to create a joint ... treatment protocols and translational research. Baptist MD Anderson Cancer ... 2015, providing a single destination for highly coordinated, multidisciplinary ...
Breaking Medicine News(10 mins):Health News:John Evans Supportive Living Community Prepares for Party on the Patio 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 2Health News:Narconon Arrowhead Raises Awareness on Alcohol Related Prevention 3Health News:In Defense of Christians Condemns Armenian Genocide 2Health News:In Defense of Christians Condemns Armenian Genocide 3Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 2Health News:Platelet-Rich Plasma, Stem Cell Therapy Now Offered By Dr. Meier At MOSM in Beverly Hills, California 3Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 2Health News:Baptist Health and MD Anderson Finalize Agreement to Transform Cancer Care in Region 3
... of menopausal symptoms. However if this is used in// conjunction ... be altered. ,Scientists of Yale School of Medicine in ... medication taken by breast cancer patients may alter the way ... not even aware of the fact that their patients may ...
... people has shown that late sleeping time may lead to glucose ... late in the night, these are the things that may have ... the new issue of Archives of Internal Medicine. For 722 men ... years in the study, the mean sleep hours was 7 hours ...
... of peppermint or cinnamon could make the drivers of motor ... of time makes the drivers of the vehicle angry, fatigued ... in the study under the conditions of three different types ... were added to the air inside the vehicle with the ...
... of having fractures, are often routinely prescribed vitamin D and ... to light the fact that this may not be true. ... fractures in the elderly people. ,The study had looked ... these people were mobile before they had a low trauma ...
... smoking was considered to be a risk factor for ... the neural degeneration more in people suffering from multiple ... of Harvard school of medicine, researchers had been able ... condition of multiple sclerosis. In a study comprising of ...
... University had found out that it is possible to generate ... first does of insulin was given to patient suffering from ... overcame its supply. Moreover, where there is availability of insulin, ... patients. One reason for such is inability of the patient ...
Cached Medicine News:
... is an endoscopic urethral implant for ... Upon implantation, the Tegress™ Implant solution ... in a Dimethyl Sulfoxide (DMSO) carrier ... reinforces the integrity of the urethras ...
... (VZ) test system is intended ... detection of VZ IgG antibody ... indirect fluorescent antibody (IFA) technique. ... confirm a recent infection or ...
... Captia™ Varicella-Zoster Virus (VZV) IgM ... intended for the detection of ... in human serum as an ... primary infection or reactivation. For ...
... Biotech Captia™ Varicella-Zoster Virus (VZV) IgG Enzyme-linked ... detection and quantitative determination of IgG antibody ... specimens may be used for the determination ... convalescent, may be used to demonstrate seroconversion ...
Medicine Products: